Clinical Trial

Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors

Study acronym: SABR-COMET 10
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
In patients with a limited oligometastatic burden (cancer has spread but is not yet considered metastatic), emerging evidence suggests that treatment of all sites of disease with ablative therapies can improve patient outcomes, including overall- and progression-free survival. The application of Stereotactic Ablative Radiotherapy (SABR) for patients with 4-10 metastatic deposits appears promising, yet it is unclear if all patients with greater than 3 oligometastatic lesions benefit from ablative therapies in terms of improved Overall Survival (OS), Progression Free Survival (PFS), or quality of life. The purpose of this study is to assess the impact of SABR, compared to standard of care treatment, on overall survival, oncologic outcomes, and quality of life in patients with a controlled primary tumor and 4-10 metastatic lesions.
Protocol Amendment History 17 amendments
This ClinicalTrials.gov record has been amended 17 times since 2018-10-24; most recent amendment 2025-09-12.
Status change: Recruiting → Active, Not Recruiting 2023-12-12
Status change: Not Yet Recruiting → Recruiting 2019-02-24
Trial Details
NCT Number NCT03721341
Lead Sponsor David Palma
Collaborators: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), British Columbia Cancer - Centre for the North, Beaston West of Scotland Cancer Centre, London Health Sciences Centre
Conditions Metastatic Tumors
Enrollment 204 participants
Start Date 2019-02-22
Primary Completion 2029-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-18